BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chirac P, Maillet D, Leprêtre F, Isaac S, Glehen O, Figeac M, Villeneuve L, Péron J, Gibson F, Galateau-sallé F, Gilly F, Brevet M. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array. Human Pathology 2016;55:72-82. [DOI: 10.1016/j.humpath.2016.04.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Hiltbrunner S, Fleischmann Z, Sokol ES, Zoche M, Felley-Bosco E, Curioni-Fontecedro A. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br J Cancer 2022. [PMID: 36138075 DOI: 10.1038/s41416-022-01979-0] [Reference Citation Analysis]
2 Kepenekian V, Bhatt A, Péron J, Alyami M, Benzerdjeb N, Bakrin N, Falandry C, Passot G, Rousset P, Glehen O. Advances in the management of peritoneal malignancies. Nat Rev Clin Oncol 2022. [PMID: 36071285 DOI: 10.1038/s41571-022-00675-5] [Reference Citation Analysis]
3 . Diffuse Mesothelioma. Tumors of the Serosal Membranes 2022. [DOI: 10.55418/9781933477190-3] [Reference Citation Analysis]
4 Cordier F, Van der Meulen J, van Roy N, De Wilde J, van Dijck H, Vanhoenacker F, Lambrechts M, Noyez V, Van de Vijver K, Ferdinande L, Dendooven A, Van Dorpe J, Creytens D. Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected! Pathology - Research and Practice 2022;231:153772. [DOI: 10.1016/j.prp.2022.153772] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hajj GNM, Cavarson CH, Pinto CAL, Venturi G, Navarro JR, Lima VCC. Malignant pleural mesothelioma: an update. J Bras Pneumol 2021;47:e20210129. [PMID: 34909922 DOI: 10.36416/1806-3756/e20210129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Guo Z, Shen L, Li N, Wu X, Wang C, Gu Z, Chen Z, Liu J, Mao W, Han Y. Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma. Front Oncol 2021;11:789244. [DOI: 10.3389/fonc.2021.789244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Emi M, Gaudino G, Yoshikawa Y, Ohmuraya M. Recent Advances in the Genomic and Proteomic Researches on Mesothelioma: What Are Novel Insights into Mesothelioma Biology? Malignant Pleural Mesothelioma 2021. [DOI: 10.1007/978-981-15-9158-7_12] [Reference Citation Analysis]
8 Shrestha R, Nabavi N, Volik S, Anderson S, Haegert A, McConeghy B, Sar F, Brahmbhatt S, Bell R, Le Bihan S, Wang Y, Collins C, Churg A. Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma. Cancers (Basel) 2020;12:E1568. [PMID: 32545767 DOI: 10.3390/cancers12061568] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
9 Hung YP, Dong F, Torre M, Crum CP, Bueno R, Chirieac LR. Molecular characterization of diffuse malignant peritoneal mesothelioma. Mod Pathol 2020;33:2269-79. [PMID: 32504035 DOI: 10.1038/s41379-020-0588-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
10 Deraco M, Zaffaroni N, Perrone F, Cabras A, Kusamura S, Guaglio M, Montenovo M, Baratti D. Peritoneal Mesothelioma: Disease Biology and Patterns of Peritoneal Dissemination. Pathology of Peritoneal Metastases 2020. [DOI: 10.1007/978-981-15-3773-8_6] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Sidorov D, Grishin N, Lozhkin M, Troitsky A, Stepanyuk I, Bykasov S, Moshurov R. Tumors of peritoneum. Treatment algorithms. Onkol Z im P A Gercena 2020;9:60. [DOI: 10.17116/onkolog2020904160] [Reference Citation Analysis]
12 Kettunen E, Knuutila S, Sarhadi V. Malignant Mesothelioma: Molecular Markers. Occupational Cancers 2020. [DOI: 10.1007/978-3-030-30766-0_18] [Reference Citation Analysis]
13 Vimercati L, Cavone D, Mansi F, Cannone ESS, DE Maria L, Caputi A, Delfino MC, Serio G. Health impact of exposure to asbestos in polluted area of Southern Italy. J Prev Med Hyg 2019;60:E407-18. [PMID: 31967100 DOI: 10.15167/2421-4248/jpmh2019.60.4.1330] [Reference Citation Analysis]
14 Vanbervliet-Defrance B, Delaunay T, Daunizeau T, Kepenekian V, Glehen O, Weber K, Estornes Y, Ziverec A, Djemal L, Delphin M, Lantuéjoul S, Passot G, Grégoire M, Micheau O, Blanquart C, Renno T, Fonteneau JF, Lebecque S, Mahtouk K. Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. Cancer Lett 2020;472:29-39. [PMID: 31838086 DOI: 10.1016/j.canlet.2019.12.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
15 Brich S, Bozzi F, Perrone F, Tamborini E, Cabras AD, Deraco M, Stacchiotti S, Dagrada GP, Pilotti S. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. Mod Pathol 2020;33:217-27. [DOI: 10.1038/s41379-019-0371-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
16 Ospina D, Villegas VE, Rodríguez-Leguizamón G, Rondón-Lagos M. Analyzing biological and molecular characteristics and genomic damage induced by exposure to asbestos. Cancer Manag Res 2019;11:4997-5012. [PMID: 31239765 DOI: 10.2147/CMAR.S205723] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
17 Shrestha R, Nabavi N, Volik S, Anderson S, Haegert A, Mcconeghy B, Brahmbhatt S, Bell RH, Bihan SL, Wang Y, Collins CC, Churg A. Well-Differentiated Papillary Mesothelioma of the Peritoneum is Genetically Distinct from Malignant Mesothelioma.. [DOI: 10.1101/632810] [Reference Citation Analysis]
18 Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, Shukin R, Bell RH, McConeghy B, Haegert A, Brahmbhatt S, Li E, Oo HZ, Hurtado-Coll A, Fazli L, Zhou J, McConnell Y, McCart A, Lowy A, Morin GB, Chen T, Daugaard M, Sahinalp SC, Hach F, Le Bihan S, Gleave ME, Wang Y, Churg A, Collins CC. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med 2019;11:8. [PMID: 30777124 DOI: 10.1186/s13073-019-0620-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 14.5] [Reference Citation Analysis]
19 Irving JA, Clement PB. Diseases of the Peritoneum. Blaustein's Pathology of the Female Genital Tract 2019. [DOI: 10.1007/978-3-319-46334-6_13] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Sciarrillo R, Wojtuszkiewicz A, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, Kusamura S, Würdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. EBioMedicine 2019;39:215-25. [PMID: 30581150 DOI: 10.1016/j.ebiom.2018.12.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
21 Chapel DB, Churg A, Santoni-Rugiu E, Tsujimura T, Hiroshima K, Husain AN. Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Lung Cancer 2019;127:69-75. [PMID: 30642555 DOI: 10.1016/j.lungcan.2018.11.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
22 Boussios S, Moschetta M, Karathanasi A, Tsiouris AK, Kanellos FS, Tatsi K, Katsanos KH, Christodoulou DK. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. Ann Gastroenterol 2018;31:659-69. [PMID: 30386115 DOI: 10.20524/aog.2018.0305] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
23 Sundling KE, Cibas ES. Ancillary studies in pleural, pericardial, and peritoneal effusion cytology. Cancer Cytopathology 2018;126:590-8. [DOI: 10.1002/cncy.22021] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
24 Sage AP, Martinez VD, Minatel BC, Pewarchuk ME, Marshall EA, MacAulay GM, Hubaux R, Pearson DD, Goodarzi AA, Dellaire G, Lam WL. Genomics and Epigenetics of Malignant Mesothelioma. High Throughput 2018;7:E20. [PMID: 30060501 DOI: 10.3390/ht7030020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
25 Shrestha R, Nabavi N, Lin Y, Mo F, Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, Shukin R, Bell RH, Mcconeghy B, Haegert A, Brahmbhatt S, Li E, Oo HZ, Hurtado-coll A, Fazli L, Zhou J, Mcconnell Y, Mccart A, Lowy A, Morin GB, Daugaard M, Sahinalp SC, Hach F, Bihan SL, Gleave ME, Wang Y, Churg A, Collins CC. BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal Mesothelioma.. [DOI: 10.1101/243477] [Reference Citation Analysis]
26 Nakano T, Shibata E, Kuribayashi K, Yoshikawa Y, Ohmuraya M. Pulmonary Malignancies (2): Mesothelioma—What Are the Roles of Genetic Factors in the Pathogenesis of Mesothelioma? Respiratory Disease Series: Diagnostic Tools and Disease Managements 2018. [DOI: 10.1007/978-981-10-8144-6_12] [Reference Citation Analysis]
27 Bhatt A, Turaga KK. Registries and Collaborative Groups in Peritoneal Surface Oncology. Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond 2018. [DOI: 10.1007/978-981-10-7053-2_21] [Reference Citation Analysis]
28 Dobra K, Hjerpe A. Malignant Mesothelioma. Serous Effusions 2018. [DOI: 10.1007/978-3-319-76478-8_11] [Reference Citation Analysis]
29 Irving JA, Clement PB. Diseases of the Peritoneum. Blaustein's Pathology of the Female Genital Tract 2018. [DOI: 10.1007/978-1-4614-3165-7_13-2] [Reference Citation Analysis]
30 Johnson TG, Schelch K, Cheng YY, Williams M, Sarun KH, Kirschner MB, Kao S, Linton A, Klebe S, McCaughan BC, Lin RCY, Pirker C, Berger W, Lasham A, van Zandwijk N, Reid G. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma. J Thorac Oncol 2018;13:258-72. [PMID: 29113949 DOI: 10.1016/j.jtho.2017.10.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
31 Serio G, Pezzuto F, Marzullo A, Scattone A, Cavone D, Punzi A, Fortarezza F, Gentile M, Buonadonna AL, Barbareschi M, Vimercati L. Peritoneal Mesothelioma with Residential Asbestos Exposure. Report of a Case with Long Survival (Seventeen Years) Analyzed by Cgh-Array. Int J Mol Sci 2017;18:E1818. [PMID: 28829357 DOI: 10.3390/ijms18081818] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
32 Villeneuve L, Passot G, Glehen O, Isaac S, Bibeau F, Rousset P, Gilly FN; RENAPE Network. The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry. Orphanet J Rare Dis 2017;12:37. [PMID: 28212684 DOI: 10.1186/s13023-017-0571-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
33 Mossman BT. Cell Signaling and Epigenetic Mechanisms in Mesothelioma. Asbestos and Mesothelioma 2017. [DOI: 10.1007/978-3-319-53560-9_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Leblay N, Leprêtre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S, Maillet D, Galateau-Sallé F, Villenet C, Sebda S, Goracci A, Byrnes G, McKay JD, Figeac M, Glehen O, Gilly FN, Foll M, Fernandez-Cuesta L, Brevet M. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas. J Thorac Oncol 2017;12:724-33. [PMID: 28034829 DOI: 10.1016/j.jtho.2016.12.019] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
35 Joseph NM, Chen YY, Nasr A, Yeh I, Talevich E, Onodera C, Bastian BC, Rabban JT, Garg K, Zaloudek C, Solomon DA. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Mod Pathol 2017;30:246-54. [PMID: 27813512 DOI: 10.1038/modpathol.2016.188] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 9.9] [Reference Citation Analysis]